3,4-dihydroxybenzohydroxamic acid has been researched along with Acquired Immunodeficiency Syndrome in 2 studies
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mayhew, CN | 1 |
| Phillips, JD | 1 |
| Greenberg, RN | 1 |
| Birch, NJ | 1 |
| Elford, HL | 1 |
| Gallicchio, VS | 1 |
2 other studies available for 3,4-dihydroxybenzohydroxamic acid and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Drug targets cellular enzyme.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Benzamidines; Disease Models, Animal; | 1999 |
In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Anti-HIV Agents; Benzamidines; Cells, Cultured; | 1999 |